NCT02721979终止2 期
A Phase 2 Study of Apalutamide in Active Surveillance Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Negative (i.e. no Residual Carcinoma) Site Directed and Systematic Prostate Biopsy Rate
研究概览
简要总结
This phase II trial studies how well apalutamide works in treating patients with prostate cancer who are in active surveillance. Testosterone can cause the growth of prostate cancer cells. Hormone therapy using androgen receptor antagonist apalutamide may fight prostate cancer by blocking the use of testosterone by the tumor cells.
详细描述
OUTLINE:
Patients receive apalutamide orally (PO) once daily (QD) for 90 days in the absence of disease progression or unacceptable toxicity.
After completion of the study treatment, patients are followed up at 180, 365, 545, and 730 days; and at years 3, 4 and 5 by medical record review.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Have signed an informed consent document
- •Be willing/able to adhere to the prohibitions and restrictions specified in this protocol
- •Written authorization for use and release of health and research study information has been obtained
- •Life expectancy >= 10 years (as determined by the treating physician)
- •Eastern Cooperative Oncology Group (ECOG) performance status =< 1
- •Histologically confirmed adenocarcinoma of the prostate as documented by a minimum 12 core prostate biopsy completed within 1-year of enrollment (note: most recent prostate biopsy must have demonstrated prostatic adenocarcinoma)
- •Favorable risk prostate cancer as defined by:
- •Very low-risk:
- •Clinical stage T1c disease
- •PSA density (PSAD) < 0.15 ng/mL
- •Gleason score 6
- •=< 2 core biopsies with =< 50% involvement of any biopsy core with cancer, or unilateral disease =< 2 core biopsies with any percentage involvement OR
- •Low risk:
- •Clinical stage =< T2a
- •PSA < 15 ng/mL
- •Gleason score 6 OR
- •Low-intermediate risk:
- •Clinical stage T1c
- •PSA < 15 ng/ml
- •Gleason 3+4 present in =< 50% of one core/site as detected by systematic biopsy or MRI/transrectal ultrasound (TRUS) fusion guided biopsy
- •Gleason 6 disease in all other cores / sites
- •Willing and qualified for active surveillance at Johns Hopkins or the University of Washington
- •Serum testosterone >= 150 ng/dL
- •Able to swallow the study drugs whole as a tablet
- •Hemoglobin >= 9.0 g/dL, (at screening), independent of transfusion and/or growth factors within 3 months prior to registration
- •Platelet count >= 100,000 x 10^9/uL (at screening) independent of transfusion and/or growth factors within 3 months prior to registration
- •Serum albumin >= 3.0 g/dL (at screening)
- •Glomerular filtration rate (GFR) >= 45 mL/min (at screening)
- •Serum potassium >= 3.5 mmol/L (at screening)
- •Serum total bilirubin =< 1.5 x upper limit of normal (ULN) (at screening) (note: in subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is =< 1.5 x ULN, subject may be eligible)
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 × ULN (at screening)
- •Medications known to lower the seizure threshold must be discontinued or substituted at least 4 weeks prior to study entry
- •Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug
排除标准
- •Prior local therapy to treat prostate cancer (e.g. radical prostatectomy, radiation therapy, brachytherapy)
- •Prior use of ARN-509 (apalutamide)
- •Have known allergies, hypersensitivity, or intolerance to ARN-509 (apalutamide) or its excipients
- •Prior or ongoing systemic therapy for prostate cancer including, but not limited to:
- •Hormonal therapy (e.g. leuprolide, goserelin, triptorelin)
- •Cytochrome P450 (CYP)-17 inhibitors (e.g. abiraterone, ketoconazole)
- •Antiandrogens (e.g. bicalutamide, nilutamide)
- •Second generation antiandrogens (e.g. enzalutamide)
- •Immunotherapy (e.g. sipuleucel-T, ipilimumab)
- •Chemotherapy (e.g. docetaxel, cabazitaxel)
- •Have any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements
- •History of any of the following:
- •Seizure or known condition that may pre-dispose to seizure (including but not limited to prior stroke, transient ischemic attack, loss of consciousness within 1 year prior to registration, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)
- •Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to registration
- •Any condition that in the opinion of the investigator, would preclude participation in this study
- •Current evidence of any of the following:
- •Uncontrolled hypertension
- •Gastrointestinal disorder affecting absorption
- •Active infection (e.g. human immunodeficiency virus [HIV] or viral hepatitis) or other medical condition that would make prednisone/prednisolone (corticosteroid) use contraindicated
- •Any condition that in the opinion of the investigator, would preclude participation in this study
- •The use of drugs known to lower the seizure threshold, including: atypical antipsychotics (e.g. clozapine, olanzapine, risperidone, ziprasidone), bupropion, lithium, meperidine, pethidine, phenothiazine antipsychotics (e.g. chlorpromazine, mesoridazine, thioridazine), and tricyclic antidepressants (e.g. amitriptyline, desipramine, doxepin, imipramine, maprotiline, mirtazapine)
- •The use of strong CYP3A4 inhibitors, including: itraconazole, clarithromycin, erythromycin, diltiazem, verapamil, delavirdine, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit juice (or grapefruits)
- •Note: If a patient is on a strong CYP3A4 inhibitor, they can be reconsidered for enrollment if they can safely stop said medication; a two week or 5 half-lives, whichever is longer, washout will be required prior to enrolling on study; subject may not resume medication while receiving apalutamide
- •Strong CYP3A4 inducers, including: phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, efavirenz, tipranavir, St. John's wort
- •**Note: If a patient is on a strong CYP3A4 inhibitor, they can be reconsidered for enrollment if they can safely stop said medication; a two week or 5 half-lives, whichever is longer, washout will be required prior to enrolling on study; subject may not resume medication while receiving apalutamide
- •Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule
研究组 & 干预措施
Treatment (apalutamide)
Experimental
Patients receive apalutamide PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
干预措施: Apalutamide (Drug)
Treatment (apalutamide)
Experimental
Patients receive apalutamide PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
干预措施: Laboratory Biomarker Analysis (Other)
Treatment (apalutamide)
Experimental
Patients receive apalutamide PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
干预措施: Quality-of-Life Assessment (Other)
Treatment (apalutamide)
Experimental
Patients receive apalutamide PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
干预措施: Questionnaire Administration (Other)
结局指标
主要结局
Negative (i.e. no Residual Carcinoma) Site Directed and Systematic Prostate Biopsy Rate
时间窗: At 90 days
Negative rate will be presented as the percent of subjects with a negative repeat biopsy, and will be calculated as: (number of patients with a negative biopsy following 90-days of apalutamide) / (total number of patients enrolled on the study) x 100. A 1-sample chi-square test will be used to compare the proportion with a negative repeat biopsy to the null hypothesis value of 20% (above). The 95% confidence interval will be computed.
次要结局
- Percentage of Patients Exiting Active Surveillance for Any Reason(At 2 years)
- Percentage of Patients Exiting Active Surveillance Due to Pathologic Reclassification(At 2 years)
- Percent of Men Undergoing Local Treatment(At 2 years)
- Local Treatment Free Survival(Up to 730 days)
- Prostate-specific Antigen Progression Rate(At 2 years)
- Prostate-specific Antigen Progression Free Survival as Defined by the Prostate Cancer Working Group 2 Criteria(At 2 years)
- Change in Radiographic Disappearance of Magnetic Resonance Imaging Detectable Prostate Cancer(Baseline to up to 90 days)
- Change in Quality of Life: FACT-P Assessment(Baseline compared to 730 days)
- Change in Quality of Life: SF-36 Physical Functioning(Baseline compared to 730 days)
- Change in Quality of Life: SF-36 Energy/Fatigue(Baseline compared to 730 days)
- Change in Quality of Life: SF-36 Emotional Well Being(Baseline compared to 730 days)
研究者
Michael Schweizer
Assistant Professor, Division of Medical Oncology
University of Washington
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Apalutamide in Treating Patients With Prostate Cancer Before Radical ProstatectomyProstate AdenocarcinomaStage IIB Prostate Cancer AJCC v8NCT03412396M.D. Anderson Cancer Center45
进行中（未招募）
2 期
Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical ProstatectomyProstatic NeoplasmsNCT04295447Universität Münster190
已完成
2 期
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate GlandLocalized Prostate CarcinomaProstate AdenocarcinomaStage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8NCT04530552National Cancer Institute (NCI)34
进行中（未招募）
2 期
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE TrialNCT03371719NRG Oncology298
进行中（未招募）
2 期
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery EmbolizationProstate CarcinomaBenign Prostatic HyperplasiaNCT04879940H. Lee Moffitt Cancer Center and Research Institute17